ABBV-066, DEUCRAVACITINIB clinical trials

A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor-blinded-Study of Risankizumab Compared to Deucravacitinib for the Treatment of Adult Subjects with Moderate Plaque Psoriasis who are Candidates for Systemic Therapy

This study is looking at two medicines, risankizumab and deucravacitinib, for adults with moderate plaque psoriasis. It compares how well they clear up skin and aims to see if switching medicine helps if the first one isn't working as well as hoped.